Scientific findings establish the effectiveness of Envigo's new approach to investigate the protective effects of vaccine candidates and anti-viral microbodies and to study asymptomatic primary genital HSV-2 infection
Envigo has been created through the integration of Huntingdon Life Sciences, Harlan Laboratories, GFA, NDA Analytics and LSR associates.
The combined company has been created through the integration of Huntingdon Life Sciences and Harlan Laboratories, and three subsidiaries: GFA, NDA Analytics and LSR associates.
SHrN is triple-immunodeficient and is ideally suited for tumor xenografts in oncology and immunology-related research applications.
CEO Brian Cass announces the Envigo brand launch
In order to provide you with a more customized experiencewhen viewing our models please select your location:
Copyright © 2016 Envigo
Copyright © 2015 Envigo